AUG 4·SEC EDGARLow
MCNAMARA KEVIN J sold $1.1M of CHE
MCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $539.51 ($1.08M total) on 2026-08-03.
StockNYSE · US · USDHealthcare · Medical Care Facilities
$CHE
CHEMED CORP
Price · $CHEvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.2M 2 txs
GRACE PATRICK P1× · $101K
10b5-1 plan0%
Top stories · $CHEMore →
AUG 4·financialcontent.com
5 Insightful Analyst Questions From Chemed’s Q2 Earnings Call
Chemed (CHE) reported Q2 CY2026 results that beat Wall Street, helped by VITAS patient volume growth and improved admission trends, and by Roto-Rooter’s commercial programs. Revenue was $673.3M vs $665M est, adjusted EPS $6.06 vs $5.60, and full-year adjusted EPS guidance $25.38 at midpoint. The article highlights analyst questions on VITAS growth sustainability and Roto-Rooter lead costs and margins.
AUG 3·SEC EDGAR
GRACE PATRICK P sold $101K of CHE
GRACE PATRICK P sold 190 shares of CHEMED CORP (CHE) at $532.00 ($0.10M total) on 2026-07-31.
CHE sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning CHE (CHEMED CORP). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CHE coverage spans insider activity, earnings and financial news.
In the last 30 days, CHE insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.2M). The most active reporter was GRACE PATRICK P with 1 filing.
What's driving CHE
This is an insider open-market sale by the CEO, with no 10b5-1 plan cited, which can modestly affect near-term sentiment but is not a fundamental change by itself.
The article frames VITAS patient-volume and admission-trend strength plus Roto-Rooter margin resilience despite higher paid-lead marketing.
This is a routine insider sale with no 10b5-1 plan disclosed, but the disclosed size is small relative to typical institutional flows.
The quarter shows upside versus expectations on both top line and non-GAAP EPS, supporting near-term sentiment and estimates.
Higher VITAS growth and an updated full-year outlook, plus ongoing buybacks, should support near-term earnings expectations.
alphai scores every news story that mentions CHE with an AI model for sentiment and relevance, and aggregates insider trades from CHEMED CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CHE
Score
MCNAMARA KEVIN J sold $1.1M of CHE
MCNAMARA KEVIN J (president and CEO) sold 2,000 shares of CHEMED CORP (CHE) at $539.51 ($1.08M total) on 2026-08-03.
2 min read
5 Insightful Analyst Questions From Chemed’s Q2 Earnings Call
Chemed (CHE) reported Q2 CY2026 results that beat Wall Street, helped by VITAS patient volume growth and improved admission trends, and by Roto-Rooter’s commercial programs. Revenue was $673.3M vs $665M est, adjusted EPS $6.06 vs $5.60, and full-year adjusted EPS guidance $25.38 at midpoint. The article highlights analyst questions on VITAS growth sustainability and Roto-Rooter lead costs and margins.
6 min readGRACE PATRICK P sold $101K of CHE
GRACE PATRICK P sold 190 shares of CHEMED CORP (CHE) at $532.00 ($0.10M total) on 2026-07-31.
1 min read
Chemed (NYSE:CHE) Exceeds Q2 CY2026 Expectations
Chemed Corp (NYSE:CHE) reported Q2 CY2026 revenue of $673.3 million, up 8.8% year on year and 1.2% above Wall Street estimates, and non-GAAP EPS of $6.06, 8.2% above consensus. Analysts expect revenue growth of about 7% and full-year EPS to rise from $23.40 to $25.61.
5 min readCHEMED CORP (CHE): Results of Operations and Financial Condition
CHEMED CORP (CHE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 che-20260728xex99.htm EX-99 Exhibit 99 CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Second-Quarter 2026 Results Full-Year Guidance Increased Due Mainly to VITAS Outperformance CINCINNATI, July 28, 2026— Chemed Corporation (Chemed) (NYSE: CHE ), whic
6 min readHow Barington’s Activist Push For Cost Cuts And Governance Changes At Chemed (CHE) Has Changed Its Investment Story
Barington Capital escalated its activist campaign against Chemed (CHE), calling for a strategic review, cost cuts, and governance changes including a new director. It cited weak oversight and two under-optimized businesses. Investors are watching Medicare reimbursement exposure and Roto Rooter margins. Chemed projects $3.1B revenue and $386.5M earnings by 2029, alongside a $3.05B buyback authorization.
6 min readHazeltree: A Tale of Two Stories Defined the First Half of 2026 for Global Hedge Funds
Hazeltree’s H1 2026 Crowding Report says hedge funds stayed heavily positioned in AI infrastructure and semiconductors despite a Middle East conflict and higher inflation. It reports long crowding in Alphabet, Apple and Meta, while short exposure rose in Amazon, Microsoft and Nvidia. Semiconductor net-long share rose from 53% (Feb) to 70% (Jun), with Texas Instruments’ long-to-short ratio up to 2.2.
3 min readLINDELL ANDREA R sold $603K of CHE
LINDELL ANDREA R sold 1,347 shares of CHEMED CORP (CHE) at $447.33 ($0.60M total) on 2026-06-09.
2 min read
Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas
Chemed Corp. (NYSE: CHE) said its wholly owned Roto-Rooter unit acquired an independent Roto-Rooter franchise covering 21 south Texas counties, including Corpus Christi, McAllen, Laredo and Brownsville, for about $12.0 million. The company operates Roto-Rooter plumbing and drain cleaning services and VITAS hospice care. The release includes standard forward-looking statement cautions.
2 min readWALSH GEORGE J III sold $219K of CHE
WALSH GEORGE J III sold 500 shares of CHEMED CORP (CHE) at $437.83 ($0.22M total) on 2026-05-29.
2 min read